stau2 Antibody

What is STAU2 and why is it important in neurological research?

STAU2 is an RNA-binding protein that plays a crucial role in the transport and localization of mRNA within neurons, which is vital for proper neuronal function and development. It is predominantly expressed in brain tissue and is involved in the microtubule-dependent delivery of neuronal RNA to dendrites, thereby influencing synaptic plasticity and the formation of dendritic spines. STAU2 belongs to the double-stranded RNA-binding protein family and shuttles between the nucleus and cytoplasm, where it associates with ribonucleoprotein particles that facilitate mRNA transport . Interference with STAU2 expression in mature neurons results in a significant reduction in dendritic spines, underscoring its essential role in maintaining synaptic structure and function .

What detection methods are validated for STAU2 antibodies?

STAU2 antibodies, such as the S-35 mouse monoclonal antibody, have been validated for multiple detection methods in research applications. The primary validated techniques include:

• Western blotting (WB): For protein quantification and molecular weight determination

• Immunoprecipitation (IP): For isolation of STAU2 protein complexes

• Enzyme-linked immunosorbent assay (ELISA): For quantitative detection in solution

When selecting a detection method, researchers should consider the specific isoforms they're targeting, as STAU2 exists in five different isoforms due to alternative splicing, which may contribute to diverse functional roles in neuronal development and plasticity .

Which STAU2 isoforms can current antibodies detect?

Current commercially available STAU2 antibodies like the S-35 monoclonal antibody can detect STAU2 protein across multiple species including mouse, rat, and human origins . In Western blot applications, researchers typically observe the predominant STAU2 band at approximately 62 kDa with a lighter intensity band appearing at ~64 kDa . These bands represent different isoforms of the STAU2 protein. When designing experiments, it's important to note that STAU2 exists in five different isoforms due to alternative splicing, which may contribute to diverse functional roles in neuronal development and plasticity. Not all antibodies may detect all isoforms with equal efficiency, so validation with positive controls is recommended for specific applications .

How does STAU2 dysregulation contribute to neurodegenerative disorders?

STAU2 protein, but not mRNA, has been found to be overabundant in various neurodegenerative disease models, including:

• Spinocerebellar ataxia type 2 (SCA2) patient fibroblasts

• Amyotrophic lateral sclerosis (ALS)/frontotemporal dementia patient fibroblasts

• ALS patient spinal cord tissues

• Central nervous system tissues from SCA2 and ALS animal models

The mechanistic relationship between STAU2 and neurodegeneration involves several pathways. Exogenous expression of STAU2 in human embryonic kidney 293 cells activates mechanistic target of rapamycin (mTOR) and triggers stress granule formation. Moreover, targeting STAU2 by RNAi has been shown to normalize mTOR in SCA2 and C9ORF72 cellular models . When STAU2 is overexpressed, it leads to increased levels of total and phosphorylated mTOR, as well as elevated levels of SQSTM1/p62 and LC3-II, consistent with impaired autophagy in SCA2 cellular and mouse models .

Interestingly, the microRNA miR-217, which is downregulated in SCA2 mice, targets the STAU2 3′-UTR. Exogenous expression of miR-217 significantly reduces STAU2 and mTOR levels in cellular models of neurodegenerative disease, suggesting a potential therapeutic approach .

What role does STAU2 play in cancer research, particularly in pancreatic adenocarcinoma?

Recent research has identified STAU2 as a novel prognostic and diagnostic biomarker for pancreatic adenocarcinoma (PAAD), revealing its potential utility in cancer therapy and drug development . STAU2 expression levels have been associated with patient prognosis in PAAD, with high expression correlating with negative prognosis.

Drug sensitivity analyses have revealed interesting correlations between STAU2 expression and treatment responses. STAU2 expression shows a negative correlation with the IC50 (half-maximal inhibitory concentration) of 5-Fluorouracil and Gemcitabine, but a positive correlation with the IC50 of Erlotinib . This indicates that patients with high levels of STAU2 mRNA are potentially more sensitive to 5-Fluorouracil and Gemcitabine but more resistant to Erlotinib, making these drugs potential targets for combination therapy in PAAD treatment strategies .

Experimental validation showed that when STAU2 was knocked down (shSTAU2) in PANC-1 cells, the IC50 values for 5-Fluorouracil and Gemcitabine increased relative to control cells, whereas the IC50 for Erlotinib decreased . These findings suggest an important role for STAU2 in modulating drug responses in pancreatic cancer.

What is the relationship between STAU2 and cellular stress response pathways?

STAU2 has been implicated in stress granule (SG) formation and cellular stress response pathways. Research has demonstrated that exogenous expression of STAU2-GFP in U2OS osteosarcoma cells leads to the formation of constitutive cytoplasmic aggregates that are positive for G3BP1, a marker for stress granules . This indicates that elevated STAU2 levels alone are sufficient to drive SG formation, even in the absence of external stressors.

The relationship between STAU2 and stress response extends to autophagy regulation. STAU2 overexpression leads to increased levels of mTOR, phosphorylated mTOR (P-mTOR), p62, and LC3-II, while levels of mTOR mRNA remain unchanged . This suggests that STAU2-mediated mTOR abundance is associated with post-transcriptional modification rather than transcriptional regulation.

In neurodegenerative disease models, where STAU2 is overabundant, there is evidence of impaired autophagy with inefficient autophagosome-lysosome fusion. Lowering STAU2 levels through siRNA treatment in both SCA2 and ALS-FTD cellular models resulted in decreased levels of mTOR, P-mTOR, p62, and LC3-II, effectively restoring autophagic pathway protein homeostasis . This therapeutic effect of STAU2 knockdown suggests a potential avenue for treating certain neurodegenerative conditions.

What are the optimal conditions for STAU2 antibody validation in experimental design?

When validating STAU2 antibodies for experimental applications, researchers should implement a multi-step validation process:

• Antibody specificity testing: Use siRNA knockdown controls to verify antibody specificity. For example, treating HEK293 cells with STAU2-specific siRNA for 4 days, followed by Western blotting against control cells treated with scrambled siRNA, can confirm specificity. Properly validated antibodies will show significant reduction in STAU2 band intensity (primarily at 62kDa with a lighter band at ~64kDa) in the knockdown samples .

• Cross-reactivity assessment: Verify that the STAU2 antibody doesn't cross-react with its paralog STAU1, which shares some structural similarities. This is particularly important in experiments examining both proteins simultaneously .

• Species validation: Confirm that the antibody performs consistently across species if working with multiple model systems. For example, the S-35 monoclonal antibody has been validated to detect STAU2 protein from mouse, rat, and human origins .

• Application-specific validation: Optimize conditions specifically for each application technique (WB, IP, ELISA) as buffer conditions, blocking agents, and incubation times may need to be adjusted for optimal performance across different experimental methods .

How can researchers effectively monitor STAU2 protein levels in neurodegenerative disease models?

Effective monitoring of STAU2 protein levels in neurodegenerative disease models requires a carefully designed experimental approach:

• Sample preparation optimization: For cellular models (such as patient-derived fibroblasts or HEK293-ATXN2-Q22/Q58 knock-in cells), standard protein extraction protocols with protease inhibitors are suitable. For CNS tissues from animal models or patient samples, specialized extraction buffers that effectively solubilize membrane-associated proteins are recommended .

• Western blot analysis protocol:

  • Use 20-40μg of total protein per lane

  • Include both STAU2 and housekeeping protein controls (β-actin, GAPDH)

  • Detect the predominant STAU2 band at approximately 62 kDa and the secondary band at ~64 kDa

  • Implement quantitative densitometry to normalize STAU2 levels to loading controls

• Context proteins to assess alongside STAU2: When studying neurodegenerative contexts, simultaneously assess:

  • Total mTOR and phosphorylated mTOR (P-mTOR)

  • Autophagy markers: p62/SQSTM1 and LC3-II

  • Disease-specific proteins (e.g., ATXN2 for SCA2 models)

• mRNA vs. protein measurement: Given that STAU2 dysregulation in neurodegenerative diseases occurs at the protein level without corresponding changes in mRNA levels, parallel RT-qPCR analysis of STAU2 mRNA can provide valuable mechanistic insights .

What strategies can optimize STAU2 antibody performance in different experimental contexts?

For optimal STAU2 antibody performance across different experimental applications, consider these context-specific strategies:

For Western Blotting:

• Optimal dilution: Use STAU2 antibody at a concentration of 100 μg/ml with dilutions of 1:500 to 1:1000

• Blocking solution: 5% non-fat dry milk in TBST (Tris-buffered saline with 0.1% Tween-20)

• Incubation time: Primary antibody incubation overnight at 4°C yields the best signal-to-noise ratio

• Detection: Use appropriate secondary antibodies (anti-mouse IgG for S-35 monoclonal antibody)

For Immunoprecipitation:

• Protein-antibody ratio: Typically 1-5 μg of antibody per 100-500 μg of total protein

• Pre-clearing: Implement a pre-clearing step with protein A/G beads to reduce non-specific binding

• Cross-linking: Consider cross-linking the antibody to beads to prevent antibody co-elution with the target protein

• Elution conditions: Optimize between harsh (reducing sample buffer) and mild (competing peptide) elution methods depending on downstream applications

For ELISA:

• Coating concentration: Optimize primary antibody coating concentration (typically 1-10 μg/ml)

• Blocking agent: BSA or commercially available blocking buffers to minimize background

• Sample dilution series: Prepare standard curves using recombinant STAU2 protein

• Detection system: HRP-conjugated secondary antibodies with appropriate substrate for colorimetric or chemiluminescent detection

How should researchers interpret conflicting STAU2 antibody results between different detection methods?

When facing discrepancies in STAU2 detection across different methods, consider these analytical approaches:

• Method-specific constraints assessment: Each detection method has inherent limitations:

  • Western blotting primarily detects denatured proteins and may miss conformation-dependent epitopes

  • IP captures protein complexes which may mask certain epitopes

  • ELISA detects soluble proteins but may miss membrane-bound forms

• Isoform-specific detection variability: STAU2 exists in five different isoforms due to alternative splicing. Different detection methods may have varying sensitivities to these isoforms. When conflicting results emerge, researchers should determine which specific isoforms are being detected by each method. Western blotting typically reveals the predominant STAU2 band at 62 kDa with a lighter band at ~64 kDa .

• Validation with multiple antibodies: When results conflict between methods, validate with alternative STAU2 antibodies targeting different epitopes. Compare monoclonal versus polyclonal antibodies, as each has different binding characteristics .

• Positive and negative controls: Always include:

  • Positive controls: Tissues known to express high STAU2 levels (brain tissue)

  • Negative controls: STAU2 knockdown samples (siRNA-treated)

  • Species controls: If working across species, ensure appropriate positive controls for each species

What are the best approaches for analyzing STAU2 expression in relation to disease phenotypes?

When analyzing STAU2 expression in relation to disease phenotypes, researchers should implement the following analytical framework:

• Multi-level analysis approach:

  • Protein level: Quantify STAU2 protein abundance through Western blotting

  • mRNA level: Measure STAU2 mRNA expression via RT-qPCR

  • Post-translational modifications: Assess phosphorylation or other modifications

  • Cellular localization: Determine subcellular distribution through immunofluorescence

• Context-dependent interpretation: In neurodegenerative disease contexts:

  • STAU2 protein (not mRNA) is typically overabundant in SCA2, ALS/FTD patient fibroblasts, and animal models

  • This protein overabundance correlates with increased mTOR activation and autophagy impairment

  • Stress granule formation may be observed in cellular models with elevated STAU2 levels

• Correlation with disease markers: Analyze STAU2 levels in relation to:

  • Autophagy markers: mTOR, P-mTOR, p62, LC3-II

  • Disease-specific proteins: ATXN2 for SCA2, C9ORF72 for ALS-FTD

  • Stress response indicators: G3BP1-positive stress granules

• Therapeutic response assessment: When testing potential therapeutic approaches:

  • Monitor STAU2 knockdown efficiency

  • Track normalization of downstream markers (mTOR, autophagy markers)

  • Assess phenotypic rescue in cellular models

  • Consider microRNA modulators like miR-217 that target STAU2

How can researchers distinguish between STAU1 and STAU2 functions in experimental models?

Distinguishing between STAU1 and STAU2 functions requires careful experimental design given their paralogy and partially overlapping functions:

• Selective knockdown experiments:

  • Use siRNAs specifically targeting STAU2 but not STAU1 (or vice versa)

  • Validate knockdown specificity by Western blotting for both proteins

  • Compare phenotypic effects of individual knockdowns versus double knockdowns

• Isoform-specific rescue experiments:

  • After knockdown, reintroduce specific isoforms of either STAU1 or STAU2

  • Assess which specific functions are rescued by each paralog

  • Construct chimeric proteins containing domains from each paralog to map functional specificity

• Distinct mechanistic pathways:

  • STAU1 has been shown to directly bind to the 5'UTR of mTOR, enhancing its translation

  • For STAU2, investigate if it targets specific mRNAs controlling autophagy or other pathways

  • Compare mRNA targets identified through RNA immunoprecipitation followed by sequencing (RIP-seq) for both proteins

• Context-dependent functional analysis:

  • While both proteins show overabundance in neurodegenerative disease models, they may have distinct contributions to disease mechanisms

  • Consider that therapeutic knockdown of one paralog may be partially compensated by the presence of the other

  • Evaluate whether combined modulation of both proteins yields synergistic or antagonistic effects

What emerging applications of STAU2 antibodies show promise in neurodegenerative disease research?

Emerging applications of STAU2 antibodies in neurodegenerative disease research show significant promise in several areas:

• Biomarker development:

  • STAU2 protein levels in patient fibroblasts could serve as peripheral biomarkers for disease progression in SCA2 and ALS

  • Correlation studies between STAU2 levels in easily accessible tissues and disease severity could establish its utility as a diagnostic or prognostic marker

  • Longitudinal studies tracking STAU2 levels before and after therapeutic interventions could provide pharmacodynamic endpoints

• Therapeutic target validation:

  • STAU2 knockdown has shown promise in normalizing mTOR levels and restoring autophagy function

  • Antibody-based approaches for monitoring STAU2 reduction in response to antisense oligonucleotides (ASOs) or siRNA therapies

  • Development of high-throughput screening assays using STAU2 antibodies to identify small molecules that modulate STAU2 function or levels

• Mechanistic pathway elucidation:

  • Chromatin immunoprecipitation (ChIP) applications to identify STAU2-associated RNA complexes

  • Proximity labeling approaches combined with STAU2 antibodies to map the dynamic STAU2 interactome in health and disease

  • Single-cell analysis of STAU2 levels and localization to understand cell-type specific vulnerabilities in heterogeneous tissues

How can STAU2 antibodies inform therapeutic development strategies for neurodegenerative conditions?

STAU2 antibodies can significantly inform therapeutic development for neurodegenerative conditions through several strategic applications:

• Target engagement and pharmacodynamic markers:

  • STAU2 antibodies can be used to confirm target engagement of therapeutic approaches aimed at reducing STAU2 levels or function

  • Western blotting and immunofluorescence with STAU2 antibodies can provide quantitative measures of therapeutic efficacy

  • Correlation between STAU2 reduction and improvement in downstream pathways (mTOR normalization, autophagy restoration) can establish mechanism-based efficacy markers

• RNA-based therapeutic development:

  • The finding that microRNA miR-217 targets the STAU2 3′-UTR and reduces STAU2 and mTOR levels suggests a potential microRNA-based therapeutic approach

  • STAU2 antibodies would be essential for validating the efficacy of such RNA-based therapies

  • Development of miR-217 mimics or other RNA-based approaches targeting STAU2 would require antibody-based validation

• Combination therapy approaches:

  • Since both STAU1 and STAU2 show similar overabundance patterns in neurodegenerative diseases, therapeutic strategies targeting both proteins might be more effective

  • STAU2 antibodies would be critical for monitoring the efficacy of such combination approaches

  • Understanding the compensation mechanisms between STAU1 and STAU2 would inform optimal therapeutic dosing and scheduling

What experimental approaches could further elucidate STAU2's role in mTOR regulation and stress granule dynamics?

To further elucidate STAU2's role in mTOR regulation and stress granule dynamics, several innovative experimental approaches could be employed:

• High-resolution live cell imaging:

  • Use fluorescently tagged STAU2 antibodies for live-cell imaging to track STAU2 localization during stress responses

  • Implement super-resolution microscopy techniques to visualize the dynamic association of STAU2 with stress granules

  • Perform FRAP (Fluorescence Recovery After Photobleaching) analysis to determine STAU2 mobility within stress granules under various conditions

• RNA-protein interaction mapping:

  • Conduct CLIP-seq (Cross-linking immunoprecipitation followed by sequencing) using STAU2 antibodies to identify the RNA targets of STAU2 in normal and disease states

  • Perform RNA immunoprecipitation (RIP) to identify mRNAs associated with STAU2 in stress granules

  • Investigate whether STAU2, like STAU1, directly binds to mTOR mRNA to enhance its translation

• Structural and functional domain analysis:

  • Generate domain-specific STAU2 constructs and use antibodies to validate their expression and localization

  • Identify which domains of STAU2 are responsible for stress granule localization versus mTOR regulation

  • Develop domain-specific antibodies to track the functions of different STAU2 domains in various cellular contexts

• Quantitative proteomics approaches:

  • Use STAU2 antibodies for immunoprecipitation followed by mass spectrometry to identify STAU2 interaction partners

  • Compare STAU2 interactomes in normal versus stress conditions to identify stress-specific interactions

  • Implement proximity labeling approaches (BioID, APEX) coupled with STAU2 antibodies to map the dynamic STAU2 proximity interactome